Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

We should not use PDL1 and other biomarkers for selecting patients for immune...

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada

Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )

Imaging and novel PET tracers: State of the art

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

Imaging and novel PET tracers: State of the art ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )

Editor's Choice for September 2016

Prof Gordon McVie - Editor in Chief, ecancer

Editor's Choice for September 2016 ( Prof Gordon McVie - Editor in Chief, ecancer )

How do cancer registries operate in the UK?

Dr Jem Rashbass - Public Health England, UK

How do cancer registries operate in the UK? ( Dr Jem Rashbass - Public Health England, UK )

Proton accelerators for cancer therapy

Dr Stephen Myers - AVO, Geneva, Switzerland

Proton accelerators for cancer therapy ( Dr Stephen Myers - AVO, Geneva, Switzerland )

When is an assay ready for the clinic?

Dr Erasmus Schneider - Wadsworth Center, Albany, USA

When is an assay ready for the clinic? ( Dr Erasmus Schneider - Wadsworth Center, Albany, USA )

IBCD 2016: Integrating assays into clinical trials

Dr Tracy Lively - National Cancer Institute, USA

IBCD 2016: Integrating assays into clinical trials ( Dr Tracy Lively - National Cancer Institute, USA )

Innovative imaging techinques to visualise drug targets

Prof Guus van Dongen - VU University Medical Center, Amsterdam, Netherlands

Innovative imaging techinques to visualise drug targets ( Prof Guus van Dongen - VU University Medical Center, Amsterdam, Netherlands )

More from ecancer